Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave.

ABSTRACT:

Objectives

To investigate the role of immunogenicity after the third vaccine dose against Omicron infection and COVID-19-compatible symptoms of infection.

Methods

First, we examined vaccine effectiveness (VE) of the third dose against the second dose during the Omicron wave among the staff at a tertiary hospital in Tokyo. In a case-control study of third vaccine recipients, we compared the preinfection live-virus neutralizing antibodies (NAb) against Omicron between breakthrough cases and their controls who had close contact with patients with COVID-19. Among these cases, we examined the association between NAb levels and the number of COVID-19-compatible symptoms.

Results

Among the 1456 participants for VE analysis, 60 breakthrough infections occurred during the Omic

SUBMITTER: Yamamoto S 

PROVIDER: S-EPMC9867771 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature